Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › Coronavirus Tests From Fosun Pharma, Osang Healthcare Receive FDA Emergency Use Authorization

Coronavirus Tests From Fosun Pharma, Osang Healthcare Receive FDA Emergency Use Authorization

Apr 20, 2020
|
staff reporter

NEW YORK ─ The US Food and Drug Administration has granted Emergency Use Authorization to Shanghai Fosun Pharmaceutical for its COVID-19 RT-PCR detection kit and Osang Healthcare for its GeneFinder COVID-19 Plus RealAmp Kit.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
12
Featured Webinar

Demystifying COVID-19 Antibody Testing

Sponsored by
Truvian

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. Sysmex America to Distribute Siemens Urine Analyzer in North America

  2. Helix Gets FDA Emergency Use Authorization for NGS-Based COVID-19 Test

  3. Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

  4. Luminex Responds to FDA Warning Letter While Ramping SARS-CoV-2 Test Manufacturing

    Premium

  5. Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.